Bone Marrow Analysis in Early-Stage Breast Cancer
Principal Investigator
David Krag, MD
Status
Terminated
Date Opened To Accrual
January 29 2007
Date Closed to Accrual
April 20 2011
Date of Study Termination
August 13 2018
Disease Site
Breast [BR]
Breast
Phase
III
Developmental Therapeutics
No
Primary Objective
The primary aim is to determine the relative risk of death associated with the presence of tumor cells in the bone marrow of patients with early-stage breast cancer.
The primary endpoint for analysis is overall survival (OS), where OS will be the time from entry into the study to death from any cause.
Patient Population
Patients with early-stage breast cancer who were to undergo breast surgery were eligible for participation.
Protocol Record Retention Dates
Date Records No Longer to be Kept by US Sites: 08/13/2021
Date Records No Longer to be kept by Canadian Sites: 08/13/2033
Target Accrual
1634
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.